IGF-1 pathway.
Downstream growth signalling through the IGF-1 receptor and its splice variants.
Insulin-like growth factor 1 is the main mediator of growth hormone's anabolic effects. Growth hormone binds its own receptor on hepatocytes, which dimerises and signals through the JAK2 and STAT5 pathway to drive IGF-1 transcription. Circulating IGF-1 then binds the IGF-1 receptor, a receptor tyrosine kinase closely related to the insulin receptor, which activates the PI3K, Akt, and mTOR cascade alongside the Ras and MAPK cascade. The result is increased protein synthesis, cell proliferation, and suppression of programmed cell death. Muscle also produces IGF-1 locally in response to mechanical loading, and this local supply is thought to matter more for tissue repair than the circulating pool does. A critical regulatory layer is the family of six IGF-binding proteins. The great majority of circulating IGF-1 is bound to these proteins rather than free, which limits how much reaches receptors at any moment and prevents excessive signalling. Several compounds in this group are engineered specifically to evade that control, using amino-acid substitutions and terminal extensions that drop binding-protein affinity dramatically. The consequence is a much larger free fraction and a far longer functional presence than native IGF-1, which is the intended effect and also the source of the main concern about them. A separate branch involves splice variants. Mechanical stress shifts IGF-1 splicing to produce a variant with a distinct carboxy-terminal E-domain, and the isolated E-peptide has been proposed to act on muscle satellite cells through a receptor different from the classical IGF-1 receptor, expanding the stem cell pool before mature IGF-1 drives differentiation. Attaching polyethylene glycol to this peptide is a stability modification rather than a change in mechanism. The honest position differs sharply between branches. Growth hormone and IGF-1 receptor biology is textbook physiology, well established in humans, and recombinant growth hormone is an approved medicine for defined deficiency states. The splice-variant branch is far weaker: independent laboratories have not consistently reproduced the proposed proliferative effect of the isolated E-peptide, and there are essentially no controlled human trials of it. Across the whole pathway, unregulated amplification of a proliferative growth signal raises theoretical concerns about promoting the growth of existing abnormal cells, and these compounds other than approved growth hormone have no established human safety record.
Peptides acting through this pathway.
FAQ.
What does igf-1 pathway do?
Insulin-like growth factor 1 is the main mediator of growth hormone's anabolic effects. Growth hormone binds its own receptor on hepatocytes, which dimerises and signals through the JAK2 and STAT5 pathway to drive IGF-1 transcription. Circulating IGF-1 then binds the IGF-1 receptor, a receptor tyrosine kinase closely related to the insulin receptor, which activates the PI3K, Akt, and mTOR cascade alongside the Ras and MAPK cascade. The result is increased protein synthesis, cell proliferation, and suppression of programmed cell death. Muscle also produces IGF-1 locally in response to mechanical loading, and this local supply is thought to matter more for tissue repair than the circulating pool does. A critical regulatory layer is the family of six IGF-binding proteins. The great majority of circulating IGF-1 is bound to these proteins rather than free, which limits how much reaches receptors at any moment and prevents excessive signalling. Several compounds in this group are engineered specifically to evade that control, using amino-acid substitutions and terminal extensions that drop binding-protein affinity dramatically. The consequence is a much larger free fraction and a far longer functional presence than native IGF-1, which is the intended effect and also the source of the main concern about them. A separate branch involves splice variants. Mechanical stress shifts IGF-1 splicing to produce a variant with a distinct carboxy-terminal E-domain, and the isolated E-peptide has been proposed to act on muscle satellite cells through a receptor different from the classical IGF-1 receptor, expanding the stem cell pool before mature IGF-1 drives differentiation. Attaching polyethylene glycol to this peptide is a stability modification rather than a change in mechanism. The honest position differs sharply between branches. Growth hormone and IGF-1 receptor biology is textbook physiology, well established in humans, and recombinant growth hormone is an approved medicine for defined deficiency states. The splice-variant branch is far weaker: independent laboratories have not consistently reproduced the proposed proliferative effect of the isolated E-peptide, and there are essentially no controlled human trials of it. Across the whole pathway, unregulated amplification of a proliferative growth signal raises theoretical concerns about promoting the growth of existing abnormal cells, and these compounds other than approved growth hormone have no established human safety record.
Which peptides act through igf-1 pathway?
IGF-1 LR3, PEG-MGF, MGF, Human Growth Hormone. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.